Tumeurs de l'ovaire à la limite de la malignité: Place de la chimiothérapie

The prognosis of borderline ovarian tumors (BOT) is globally excellent and surgery is the cornerstone of treatment. The place of post-operative treatment in BOT remains complex and controversial in some situations. Only a small subset of patients with poor prognostic factors may benefit from chemotherapy, but these factors (clinical, biological or histologic) are yet to be clearly defined. Responses to chemotherapy have been reported in some invasive implants or for bulky disease, but the overall benefit for the patients is not clear (survival, quality of life, treatment toxicity). Some authors propose adjuvant treatment only for patients with invasive implants, and others only in the case of aneuploid invasive implants. The question, therefore, remains open: can some patients with BOT benefit from adjuvant chemotherapy?